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Abstract
Background: New psychoactive substances (NPS) have been increasingly consumed by people who use drugs
in recent years, which pose a new challenge for treatment services. One of the largest groups of NPS is synthetic
cannabinoids (SCs), which are intended as a replacement to cannabis. While there is an increasing body of research
on the motivation and the effects associated with SC use, little is known about the subjective interpretation of
SC use by the people who use drugs themselves. The aim of this study was to examine the experiences and
personal interpretations of SC use of users who were heavily dependent on SC and are in treatment.
Methods: A qualitative research method was applied in order to explore unknown and personal aspects of SC use.
Semi-structured interviews were conducted with six participants who had problematic SC use and entered treatment.
The research was conducted in Hungary in 2015. We analyzed data using interpretative phenomenological analysis (IPA).
Results: Participants perceived SCs to be unpredictable: their initial positive experiences quickly turned negative. They
also reported that SCs took over their lives both interpersonally and intrapersonally: the drug took their old friends away,
and while initially it gave them new ones, in the end it not only made them asocial but the drug became their only
friend, it hijacked their personalities and made them addicted.
Conclusions: Participants experienced rapid development of effects and they had difficulties interpreting or integrating
these experiences. The rapid alteration of effects and experiences may explain the severe psychopathological
symptoms, which may be important information for harm reduction and treatment services. Since, these experiences
are mostly unknown and unpredictable for people who use SCs, a forum where they could share their experiences
could have a harm reducing role. For a harm reduction point of view of SCs, which are underrepresented in literature,
it is important to emphasize the impossibility of knowing the quantity, purity, or even the number of different SC
compounds in a particular SC product. Our study findings suggest that despite the adverse effects, including a rapid
turn of experiences to negative, rapid development of addiction and withdrawal symptoms of SCs, participants
continued using the drug because this drug was mostly available and cheap. Therefore, a harm reduction approach
would be to make available and legal certain drugs that have less adverse effects and could cause less serious
dependence and withdrawal symptoms, with controlled production and distribution (similarly to cannabis legalization
in the Netherlands).
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Background
New psychoactive substances (NPS) have been increas-
ingly used by people who use drugs in recent years, which
poses a new challenge for treatment services and re-
searchers [1]. NPS are sold as replacements to illicit drugs,
but they often contain unknown compounds. They are
produced in small laboratories or on a commercial scale
in clandestine factories by organized crime groups [2].
One of the largest groups of NPS is synthetic cannabi-
noids (SCs), which are intended as a replacement to can-
nabis [3]. SCs appeared on the drug market in the mid-
2000s and were sold as herbal smoking mixtures; since
then, hundreds of different compounds have appeared [2].
In Hungary, NPSs appeared in 2010 and rapidly
dominated the illicit drug market [4]. The number of
seizures of SC—also known as “herbal”, “bio-weed”, or
“sage”—was nearly double the number of seizures of
herbal cannabis in 2014. The range of substances
found in the products follows the changes in legisla-
tion: between one and two dominant active substances
could be found on the market in each individual
period. After the individual substances had become
regulated, their presence on the drug market dropped
considerably and their places were taken over by new
substances (that were not yet regulated) within 1–
3 months in the period of 2011–2014 [5]. The dynam-
ics of these processes changed in 2015, as the scope
of the substances that could be traded without any
criminal consequences was narrowed drastically by the
expansion of the generic regulation. By the end of the
year, the place of ADB-FUBINACA, which was legal
until then and dominant in seizures, was overtaken by
AMB-FUBINACA and 5F-AMB, regardless that these
substances had already been controlled since October
2014 (in Hungary substances are banned compound-
by-compound [5]). Users obtain drugs from acquain-
tances and friends or from the internet [5].
Motivations to use SCs include their easy availability,
legal status, low price, and inability to be detected by
standard drug tests [6–8]. Other motivations to use
include the wish to experience pleasant feelings, recre-
ational effects, and relaxation [9, 10]. The lack of safety
information may lead to the incorrect assumption that
SCs are safe [11, 12]. Compared to cannabis use, the
consumption of SCs may be associated with more
adverse and unpredictable physical and psychological ef-
fects [10, 13–15], although people who use SCs reported
subjective experiences that are similar to the use of
cannabis, and they also described unique effects that are
very different from other kind of drugs [12]. In addition,
in the study of Winstock and Barratt [16], the effects of
SCs last for a shorter time and they are more intense
compared to cannabis, and many undesired effects have
also been described by participants.
In a study by Vandrey et al. [12], 87% of people who
use SCs reported having positive effects (e.g., they felt a
pleasant high, stimulated, and energetic), but 40% re-
ported negative or unwanted effects (e.g., dry mouth,
heart racing, and paranoia). A subset of respondents felt
unable to cut down or stop SC use (38%), experienced
tolerance (36%), used for longer periods than originally
intended (22%), and had interference with other activ-
ities (18%). Barratt et al. [9] found that 68% of the people
who used SC reported at least one side effect, such as
decreased motor coordination, fast and irregular heart-
beat, dissociation, dizziness, and psychosis.
Winstock et al. [17] conducted a research study among
people who used SC who sought emergency medical
treatment following their SC use. They found the rela-
tive risk of severe side effects associated with use of SCs
to be 30 times higher compared to that of cannabis (SC
is a full agonist and THC is a partial agonist of the CB1
receptor [18, 19]). Respondents reported more adverse
symptoms after the consumption of SCs versus cannabis,
including panic, paranoia, anxiety, and aggression, and
they used emergency services more often as well.
There is a growing body of literature on clinical case
reports about severe consequences of SC use. The con-
sumption of the drug leads to emergency room visits,
though clinical treatment often remained short and
symptomatic [13, 15]. Castaneto and colleagues [13]
conducted a literature review on acute SC intoxication
and found that patients reported that intoxication oc-
curred within 2–5 h and lasted for about 24 h. Treat-
ment to relieve symptoms included benzodiazepines and
intravenous saline solution. In a systematic review, Tait
et al. [20] summarized the adverse events arising from
SC use. They found that major complications included
cardiovascular events, acute kidney injury, generalized
tonic-clonic seizures, psychiatric presentations, and
hyperemesis, and typically involved young males with
tachycardia, agitation, and nausea requiring only symp-
tomatic care with a length of stay of less than 8 h. High
intoxication level was reported by cannabis users who
reported floating feelings, being drowsy, a sensation of
time alteration, less sociability, more talkativeness,
worsening memory, inability to think clearly, paranoia,
increased sexual pleasure, sleep difficulties, hallucina-
tions, and decreased sexual drive [21].
According to clinical case reports, the withdrawal
symptoms of SCs are similar to cannabis but more se-
vere [22–24]. Withdrawal symptoms including agitation,
irritability, anxiety, and mood swings were reported by
people who used SCs [25]. In a study by Van Hout and
Hearne [26] that examined the experience of SC with-
drawal, participants described intense cravings, compul-
sive all-consuming seeking, use and re-dose behaviors,
and a fear of the psychiatric and self-harms caused
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during withdrawal. Cannabis dependence syndrome
could occur with heavy chronic use in individuals who
report problems in controlling their use and who con-
tinue to use the drug despite experiencing adverse per-
sonal consequences [27]. Wiesbeck et al. [28] conducted
a study in a large population to evaluate marijuana with-
drawal symptoms. Almost 16% of the most frequent
marijuana users (who had used the drug daily for an
average of almost 70 months) experienced withdrawal
syndrome. These symptoms included nervous tense,
restlessness, sleep disturbance, and appetite change.
Every-Palmer [29] examined psychosis among people
who used SC and found that anxiety and psychosis symp-
toms were reported after SC use and lasted between 2 days
and several weeks. Müller et al. [30] reported a case where
a patient’s psychotic symptoms that had developed as a re-
sult of prior cannabis consumption not only worsened
after subsequent SC use but the patient also started ex-
periencing auditory and paranoid hallucinations that he
never had before. Bassir et al. [31] compared clinical pre-
sentations of SC users with cannabis users in a psychiatric
inpatient setting and found patients who had smoked SC
where most likely to experience psychosis, agitation, and
aggression than those who only smoked natural cannabis.
Bilgrei [32] analyzed discussions on experiences of SC
use in posts of an online drug forum and in interviews
with forum participants. The study illustrates the process
of alteration of experiences from positive to negative
during the consumption of SCs. While there is an in-
creasing body of research on the motivation and the ef-
fects associated with SC use [6–10] and Bilgrei [32]
examined experiences based on the forum participants’
accounts, little is known about the subjective interpret-
ation of SC use by the people themselves who used SCs.
The aim of this study was to examine personal interpre-
tations of experiences derived from the use of SCs.
Meshack et al. [7] suggests that qualitative research of-
fers an excellent opportunity to uncover subjective
aspects of personal motives and social norms in connec-
tion with drug consumption. Therefore, the aim of our
study was to assess the experiences of SC use and
analyze subjective interpretation of experiences of people
who had problematic SC use, by means of interpretative
phenomenological analysis (IPA), a qualitative research
tool that works with a person-centered approach [33].
Methods
Participants
The current study was conducted in two Hungarian
drug rehabilitation centers that work with a recovery ap-
proach and require abstinence. The participants
attended the treatment voluntarily. Based on the meth-
odology of IPA, a purposive sample was recruited [33]
among the treatment participants. According to the
methodology of IPA, the idiographic inquiry [33] re-
quires a homogenous and small sample. According to
Smith et al. [33], the recommended sample size for an
IPA study is three to six interviewees. Therefore, the
current study involved six male patients (aged 20–
27 years) who were self-identified SC users. No female
users were available. Before the analysis, they had been
using SCs for at least 2–6 years, and at the time of the
study they had been abstinent for at least 1 month. It
was assumed that SCs were the dominant components
of the substance that they smoked. The study focused on
a particular sub-group of the SC user population: people
who had problematic SC use and entered treatment.
Due to their abstinence, the effects of the drug did not
influence participants’ responses, and they could de-
scribe their experiences also from an outsider’s perspec-
tive. Additionally, by using IPA, the researcher could
examine processes: how experiences could change over
time [33] and over the addiction process, as many previ-
ous IPA studies explored experiences of people who
used drugs in recovery [34–36].
The participation in this study was voluntary, and we
use pseudonyms for the participants to protect their
identity. Information about their sociodemographic
characteristics are presented in Table 1. The Institutional
Review Board at Eötvös Loránd University approved all
study protocols.
Data collection
For this study we conducted semi-structured interviews
by using open-ended questions. The interviews lasted
45–60 min. In IPA studies, participants are perceived as
experts on the subject, and therefore the interview sched-
ule should allow ample opportunity for them to tell their
stories, and should be flexible enough to go into novel
areas and produce richer data [37]. The interview sched-
ule contained the following questions (which were modi-
fied in the light of participants’ responses; [37]): “Tell me
about your experiences of SC use”, “How did you see
yourself, when you used the drug?” How did others see
you, when you used the drug?” “How are the experiences
of SC use are different from using other drugs?”
Data analysis
The interviews were transcribed verbatim, and we an-
alyzed data using IPA. During the analysis, we applied
the aspects of IPA: the accounts of six participants
were detailed enough to track the participants’ sense-
making of their experiences. IPA works with “double
hermeneutics”, where the participants try to interpret
their experiences, and the researcher tries to interpret
the participants’ interpretation of their experiences
[33]. During the analysis, initial notes or comments
were added upon close and multiple readings of the
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interview transcripts. Through making initial notes
and comments, the researcher captured the meaning
of the experience in each participant’s accounts.
During this deep and intense analytical work (double
hermeneutic), which is often explained by the “her-
meneutic cycle” (the researcher steps into the
participants’ meaning making process and analyzes it
from an interpreter’s perspective, see [33]), “emergent
themes” are formed. In the second stage, patterns and
themes across the “emergent themes” are identified and
clustered into more abstract “master themes” [33, 37]. SK,
JNP, and JR determined the themes and the emerging
themes and reach consensus. Themes grouping to emer-
gent themes were revised by the second group of authors
(BB, TTK, KK, VAG). A consensus was then reached re-
garding the emergent themes. According to Rodham et al.
[38], the reliability could be ensured during the IPA ana-
lysis by the shared analysis of researchers. The analysis fo-
cused on participants’ interpretations of their experiences
derived from the use of SCs. The emergent and master
themes are presented in Table 2.
Results
Participants in this study interpreted their personal
experiences of using SCs. Due to the novel effects of
the drug, they perceived SCs to be unpredictable (first




Participants started using SCs by recommendations of
others in their user group or this was the first drug they
have tried. They reported that the effects of the drug
were very different from those of other drugs; therefore,
they perceived the effects of SCs to be unpredictable and
that big differences in the effect could be observed at
each drug consumption episode.
Everybody has different experiences about it, when I
smoke, I feel normal, I feel it a little bit inside, but I
do not look different. And he (a friend) smoked once
and passed out for at least two hours (Ricsi)
According to their accounts, the impact of the drug on
the user was also unpredictable. They did not experience
this unpredictability about themselves in case of other
drugs.
When I used mef (mephedrone) I got the same feeling
as I had when I was young. I was in a good mood, I
could talk to anyone, I was good with everyone, and I
was just talking and talking…the bio (bio-weed) is
dangerous I cannot realize myself, I don’t care about
anything. This is illusory, it can change you, it can make
you sick, anything can happen, you can go crazy, and
you can do things that destroy your life. (Jerob)
SCs are described as being unpredictable due to the
novel effects, which could be different in comparison to
the previous SC experiences and experiences of using
other drugs. Participants mentioned multiple unpredict-
able physical and psychological effects. Even after pro-
longed use, SCs could still evoke some unusual
experiences, which are more intense and faster than in
case of cannabis and other drugs.
Cannabis is usually… two and a half hours… the
bio-weed has a forty-five–minute effect at most.
This is a big difference. But it would be impossible
to tolerate two and a half hours of this kind of
effect that the bio-weed has. This experience is
brutal. (Szilveszter)
Table 1 Participants’ sociodemographic characteristics. (Participants’ names have been changed to protect their identities)
Name Age Sex Marital status Highest educational attainment Duration of SC usage (year) Time spent in treatment
Ricsi 27 Male Single High school 2 1 year
Attila 20 Male Single Elementary school 3.5 1 month
Zsolt 23 Male Single High school 6 2 months
Levente 22 Male Single Elementary school 6 1 month
Jerob 20 Male Single Elementary school 2.5 3 months
Szilveszter 21 Male Single Elementary school 2 6 months
Table 2 Emergent and master themes




Rapid alteration of experiences from positive to
negative
2. SCs take over
people’s lives
Interpersonal context: SCs both take away old
friends and give new ones
Interpersonal context: becoming asocial
Interpersonal context: the drug becomes a friend
Intrapersonal context: the drug hijacks the
personality
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Some participants’ perception of the drug was paranoid,
and they used metaphors to express their uncertainty of
unpredictable effects of the drug and their vulnerability
against it. They often characterized it as a danger or com-
pared it with a virus or an epidemic.
This is a kind of virus or epidemic, or I don’t know
what… it can infect everyone and can take anyone to
the bottom (Jerob).
Rapid alteration of experiences from positive to negative
SCs are described as being unpredictable, because at
the beginning, they had some positive effects, of
which participants mentioned relaxation and recre-
ational aspects. But after a few consumptions, their
experiences rapidly turned negative, and addiction ap-
peared. Then the aim of consumption was no longer
to reach the positive effects, but to avoid withdrawal
symptoms. The participants continued the use of the
drug in spite of negative experiences due to the rapid
appearance of addiction and also because this drug
was mostly available.
At the beginning you can eat more, you are in a good
mood… you can see positive things. But later it turns
into its opposite, I couldn’t eat, I was lazy, even if I
had the drug. (Attila)
I had positive experiences about this, but as time went
by, I saw many disadvantages of it. (Zsolt)
I felt I became addicted…I couldn’t sleep, I smoked it
in vain, because I woke up in every hour in the night
to smoke until morning. When I woke up in the
morning my first thoughts were about how can I get
some more again. (Levente)
SCs take over people’s lives
The participants reported fast alteration of their experi-
ences from positive to negative and felt that they had
lost control over their behavior as well as their physical
and psychological conditions. Due to these unpredictable
effects, they felt the drug hijacked their lives. The hijack-
ing effect of the drug was perceived in both interper-
sonal and intrapersonal contexts.
Interpersonal context: SCs both take away old friend and
give new ones
Interviewees described that through using the drug they
got involved with a company (a user group) that gave
them a sense of belonging, though relationships had a
purpose; they meant a sure source to obtain the drug.
I belonged to a group where I didn’t want to belong,
but I was there, because the drug was there. (Zsolt)
Later participants realized that these relationships
were worthless, but at the same time they lost their
other relationships (such as family and friends), and they
perceived the drug took them away, due to the turning
inward and isolative effects of SCs.
Sometimes we didn’t think about it, that we can hurt
people, who really loved us. People who raised us and
always were there for us. (Levente)
Interpersonal context: becoming asocial
Social and personal effects of the drug that partici-
pants reported included turning inward and becoming
asocial. As this happened against the participants’
will, they perceived that the drug hijacked them. In
these accounts a process emerged, where first the
drug gave new friends, but later it gradually took it
away, because it strengthened participants’ egoism
and disinterest in social connections. They retreated
from their social world, hid in their room, and pre-
ferred to use SCs alone.
I started to use the drug with my friends, then I
became completely asocial. So, I bought my bio-weed
and I smoked it at home at night. (Zsolt)
When I smoked the bio-weed, I plunged in my ear-
phone and the whole world switched off, and there
was only me. During those times I did not like talking
to anyone. (Ricsi)
When I smoked I was wallowing in self-pity, I felt
sorry for myself, I was alone, I didn’t care about any-
body else, I hated everyone. (Jerob)
Interpersonal context: the drug becomes a friend or a
partner
Participants perceived the drug as a friend or a
partner, which—even though it made them turn
inward—could help overcome loneliness. “I was so
lonely,… bio’ was my friend, because it was always
there, when nobody else was, it always made it pos-
sible to be there for me.” (Jerob)
In later stages of participants’ drug use carrier, SCs
become the most important thing and the only thing
that they perceive. Participants withdraw from their
social world and everyday life, and all their thoughts and
activities focus on SC consumption.
You become unconcerned about your things, for
example your clothing, your hair, and etc. you don’t
care about these things, only to have the drug. When
I woke up I smoked, if I had it. If I didn’t have the
drug, I roamed until I got some (Attila)
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On the other hand, SCs become an elementary need, a
basic part of life, without which withdrawal symptoms
appear: “When I had no money or possibility to get
some, it felt like I was going to die without it. It was to
me like food or water for normal people.” (Zsolt)
Intrapersonal context: the drug hijacks the personality
Participants mentioned the strong impact of SCs on their
mental states, more specifically a temporally change in
consciousness and behavior that lead to losing control.
This is why they felt they were hijacked by the drug.
During that time (of consumption), I felt like my body
was controlled by someone else, like it wasn’t me, I
couldn’t control it. (Levente)
At the end I sank into it, I couldn’t remember
what I did ten minutes before, if someone asked
me about it, I couldn’t answer it, so it influenced
my life so badly. (Attila)
The drug totally distorted my personality, it turned
myself inside out… it made me blunt, and switched
off my brain. (Zsolt)
By saying that the drug hijacked them, participants
tried to describe their experience of addiction, which
was perceived as compulsive drug use.
You become blunt, like if you don’t know about
yourself, your body desires the drug so much, so you
smoke. You know it is bad, but you want the drug and
it wants you, it is not good, but you smoke it
compulsively. (Attila)
It is impossible to distinguish the experiences of drug
use and addiction in these accounts. Due to the rapid
development of addiction that was reported by the par-
ticipants, the experiences of drug use are the same as
the experience of addiction; thus, participants mentioned
predominantly negative experiences.
I think this bio-weed causes addiction the fastest, be-
cause I have not experienced this kind of addiction
before, not with any other drug. (Levente)
Participants often mentioned their first thoughts in the
morning were all about the drug: “When I opened my eyes,
it was already prepared around me in the bed: the filter, the
paper and fresh tobacco” (Ricsi). And every thought they
had was about the acquisition and consumption of the
drug: “In the end I was so addicted that I went to bed with
it, I woke up with it every hour, and I was unconscious, and
then I woke up to realizing that I was smoking it.” (Attila)
Description about both the addiction of the body and
psyche emerged in the accounts, especially in presenta-
tions of withdrawal symptoms. The addiction of the psy-
che became apparent in anxiety attacks, craving, feeling
of guilt, and excruciating desire for the drug, which the
participants perceived as the drug hijacking their
thoughts. The addiction of the body was defined by
withdrawal symptoms including tremor, passing out, and
insomnia. In both cases, participants felt unable to con-
trol the symptoms and their addiction, so they perceived
being vulnerable.
I was sweating, I couldn’t sleep, my nap was numbing,
I had many physical effects… I desired the drug more
and more, I became stressful, I became neurotic, and
at the end I could not live without it. (Attila)
I smoked at night and I fell asleep, two hours later my
body woke me up to smoke again. (Zsolt)
Discussion
In this study we assessed the experiences of SC use.
During the analysis we utilized IPA, a qualitative re-
search method that is able to assess personal experiences
and examine how the participants interpret a particular
experience which is significant for them [33], as such ex-
periences of drug use or addiction could be a significant
experience [34, 35]. IPA examines processes of personal
meanings (instead of consequences), and how experience
could change over time [33, 39]. Participants perceived
SCs to be unpredictable and felt paranoid about the
drug: their initial positive experiences quickly turned
negative. They also reported that SCs took over their
lives both interpersonally and intrapersonally: the drug
took their olds friends away, and while initially it gave
them new ones, in the end it not only made them asocial
but the drug became their only friend. At last, it hijacked
their personalities and made them addicted.
Unusual physical and psychological effects, psychotic
and dependence symptoms, which were described by
previous research [12, 16, 23], were also reported by the
participants in this study. The appearance of negative
effects happens rapidly; thus, participants barely recount
positive experiences [6–8, 12, 16, 32]. The rapid devel-
opment of tolerance, the experiences of addiction (e.g.,
craving and thoughts about smoking being the first
things in the morning), lost control, and fears around
adverse effects that we found in this study were also
reported by Van Hout and Hearne [26].
According to participant accounts, the rapid development
of negative experiences is the biggest difference between
SCs and other drugs. In a qualitative study with people who
used mephedrone [40], participants recalled mostly positive
experiences (including euphoria, wellbeing, talkativeness).
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Adverse side effects were also reported as necessary com-
ponents of the overall mephedrone experience, which was
perceived as largely positive. Lee et al. [41] found that
people who used ecstasy reported positive and predictable
negative effects. The experience patterns of gamma hydro-
xybutyrate (GHB) reported by people who used the drug
were also very similar [42]. The effects of GHB use were
perceived mostly positive (such as euphoria, relaxation, in-
creased sexual desire), but participants reported that nega-
tive effects were necessary in order to reach the desired
effects of GHB. These risks could be controlled with the
presence of a user group [42].
According to the accounts of participants in our study,
the use of SCs evoked unpredictable and severe effects
such as psychosis, as it was also described by Every-
Palmer [29]. As such, the consumption of SCs could cause
not only temporal psychotic symptoms but also persistent
ones [30]. Due to the rapid alteration of experiences and
psychotic symptoms, participants perceived the effects of
SCs unpredictable, which explains the paranoid percep-
tions. It is important to note that we did not have infor-
mation about what kind of SCs participants use during
their drug consumption—usually neither the people who
use nor the dealers know what actual compounds are on
the market. This also could be a factor of unpredictability.
Furthermore, the changing experience of positive to nega-
tive effects could be related to legislative changes that have
led to more toxic SCs being used to make the products.
As Barratt et al. [9] outlined, JWH-018 did not appear to
have any more toxicity or likelihood to cause psychosis
than natural cannabis. However, as Bright et al. [43]
demonstrate, there is a complex interface between moral
panic in the media, reactive legislation, and increased
harm. This interplay between legislative changes and
Hungarian media—where the portrayal of NPS could
enhance moral panic [44, 45]—could contribute to the
emergence of new SCs with increased toxicity.
Participants experienced a strange sense of self (the
drug changed them, they became asocial, and the drug
made them do things that they would have never done
when they are sober) and they felt they were controlled
or even hijacked by the drug. The narrative of a drug
“taking over” one’s life is a personification of the drug
(which is an old narrative of anti-drug propaganda, see:
[46, 47]), may have been used here as a rationalization
or justification of their own problematic behavior.
Participants described asocial behavior as another im-
pact of SC use. Though addiction in general is associated
with a retreat from social connections and an avoidance
of the outside world [48], people who used other drugs
than SCs including mephedrone, ecstasy, and GHB
reported increased sociability, talkativeness, and loss of
social (and other) inhibitions due to the effects of the
drugs [40–42]. However, isolation and turning inward
seem to be the consequences of SC use, and therefore
SC use is a potential mediator of asocial behavior [29].
Psychoactive substance user groups can function as a
risk management strategy and a place to share the prob-
lems derived from drug consumption [40, 42, 49]. Al-
though the presence of the user group could help to
control the unpredictable effects of SCs, people who use
SCs, however, often leave the user group.
Boserman [50] analyzed diaries of people who used
cannabis and utilized IPA to explore experiences of can-
nabis use. When we compare those results with the ex-
perience of SCs use in this study, some similarities and
some differences emerge. The experience of cannabis
use is mostly positive and serves as a ritual or social and
recreational action. Cannabis is regarded vital in order
to re-equilibrate the lost balance of life. Due to fast alter-
ation of experiences derived from SC use, however, par-
ticipants in this study reported a predominance of
negative experiences. The ritualistic approach provides a
closer and intimate relationship with cannabis (the par-
ticipants fondle and respect the drug), while users’ rela-
tionship with SCs is rather paranoid.
Since the toxicity profiles of NPS may be also very dif-
ferent to those of traditional drugs and hard to identify its
health risks, and it is difficult to estimate its consumption
levels, which may not be detected by conventional drug
screens [51], it may be important to involve personal re-
ports of NPS use in harm reduction and clinical treatment
which are rather provide services according to “classical”
drug harms [52]. The described experiences by the partici-
pants of the current study outlined the subjective aspect
of SC harms including clinically significant withdrawal,
acute mental health, and overdose symptoms (e.g., [25])
that reinforce the urgent need of harm reduction and
treatment services’ enhanced preparedness.
Our study has several limitations. Based on the meth-
odology of IPA, a small homogenous sample was re-
cruited, which may question the study’s generalizability.
In addition, only male participants attended, so our re-
sults may not apply to women. For this study, a purpos-
ive sample was recruited and consisted only of SC users
who were in treatment (presumably they experienced
problems with SC use). In addition, people who use SCs
recreationally or who are not in treatment may under-
stand their experiences differently. An additional import-
ant limitation is that our study participants had assumed
but were unable to confirm that they had been using
SCs. Therefore, the experiences may vary depending on
whether they had actually been using SC or maybe an-
other substance, e.g., URB-579 (see Nakajima et al. [53])
or various other chemicals that have been found on
synthetic cannabis products ([13, 54]).
The narratives of drug use experience (such as drug
“taking over” or “hijacking” personality) reflect the
Kassai et al. Harm Reduction Journal  (2017) 14:9 Page 7 of 10
subjective views of the respondents, and this may be in
part a result of the treatment setting, as well. Further
research to explore the experiences of people who use
SCs and not in treatment for drug problems is sug-
gested. During the interviews, the participants of this
study solely focused on the effects of the drug use, so an
additional limitation of the study is the absence of infor-
mation how other factors, such as individual factors, and
biopsychosocial, social, and cultural contexts might
shape the effects and harms of SC use. An additional
limitation could be the absence of reports of other drug
experiences which were not as emphatic in the accounts
as experiences of SC use.
The importance of other factors in the examination of
drug use is increasingly being recognized on research on
other drugs. Duff [55] used the word “assemblage” to de-
scribe drug use as an act that is a network with many
persons and highlighted the context’s impact on drug
use practice and experience. The framework of “risk en-
vironment” developed by Rhodes [56] describes drug
harms as products of social situations and environments
in which individuals participate. These suggest the shift
of responsibility for drug harms and the focus of harm
reduction from the individual alone to social and polit-
ical institutions which have a role in harm production.
In Hungary, there is a noticeable growth of new psycho-
active substance use, while availability of harm reduction
services is very limited [4, 57].
Conclusions
Our study suggests that the comparison of SCs to can-
nabis may be misleading: many people who use SCs,
smoke them as an available alternative for cannabis and/
or other drugs, but the use of SCs is often associated
with more negative experiences (that are different from
other drug experiences). Due to the rapid development
of effects, participants had difficulties interpreting or
integrating their experiences. Since these experiences are
mostly unknown and unpredictable, a forum where
people who use the drug could share their experiences
could have a harm-reducing role (e.g., [58]). The rapid
alteration of effects and experiences may explain the
severe psychopathological symptoms, which may be
important information for harm reduction and treat-
ment services, where treatment staff should be aware of
unpredictable mood changes.
From a harm reduction point of view, SC is underrepre-
sented in harm reduction literature. Therefore, it is im-
portant to emphasize the impossibility of knowing the
quantity, purity, or even the number of different SC
compounds in a particular SC product (e.g., [59]). Another
important aspect could emerge: people who use SCs do
not (or rarely) access harm reduction services (while intra-
venous substance users visit these services, for example,
needle exchange program, more often [4, 57]). People who
use SCs rather utilize emergency and toxicology treat-
ments only when they experience very adverse effects.
Therefore, nurses of health care services have the possibil-
ity to give messages of harm reduction, for example, that
people who use drugs should do it in a user company (to
control its effects), or people who use drugs should con-
sume them in smaller quantities each time. Also, staff of
emergency treatment and toxicology has the possibility to
offer people who use drugs a treatment spot in rehabilita-
tion settings.
Our study findings suggest that despite of the ad-
verse effects, including a rapid turn of experiences to
negative, rapid development of addiction and with-
drawal symptoms of SCs, participants continued using
the drug because this drug was mostly available and
cheap. Therefore, a harm reduction approach would
be to make available and legal certain drugs that have
less adverse effects and could cause less serious
dependence and withdrawal symptoms, with controlled
production and distribution (similarly to cannabis legalization
in the Netherlands).
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